Biologics are part of what Syncona calls the “Second Wave” of technologies in healthcare and are dominated by large pharmaceutical companies.
Syncona targets innovative technologies in the space and our company Anaveon is a strong example of this.
value of biologics portfolio
Syncona Board seats
*Unless stated all financials at 31 March 2021